

10/590790

IAP12 Rec'd PCT/PTO 25 AUG 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV 755073275 US, on the date shown below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 25, 2006

Signature:

(Peter C. Lauro)

Docket No.: 66073US(49949)
(PATENT)

IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)
(National Phase of International Appln.: PCT/EP2005/050902
Publication No. WO2005/082375 A2)

In re Patent Application of:

Enrico Colli

International Application No.:
PCT/EP2005/050902

International Filing Date: March 1, 2005

Confirmation No.: N/A

Application No.: Not Yet Assigned

Filed: Concurrently Herewith

Art Unit: N/A

For: *TREATMENT OF INTERSTITIAL CYSTITIS
WITH VITAMIN D COMPOUNDS*

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicant invites the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicants respectfully request that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new U.S. national phase patent application submitted herewith.

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they have

U.S. National Phase Application of
PCT/EP2005/050902
Information Disclosure Statement

previously been transmitted by the International Bureau, along with the International Search Report, to all the Designated Offices in the corresponding international patent application No. PCT/EP2005/050902, filed March 1, 2005. A copy of the International Search Report is enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicant submits that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 66073US(49949). A duplicate copy of this paper is enclosed.

Dated: August 25, 2006

Respectfully submitted,
Peter C. Lauro

By

Peter C. Lauro, Esq.
Registration No.: 32,360
EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874
Boston, Massachusetts 02205
(617) 439-4444
Attorneys/Agents For Applicant

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV 755073275 US, on the date shown below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 25, 2006 Signature:


(Peter C. Lauro)

Docket No.: 66073US(49949)
(PATENT)

IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)
(National Phase of International Appln.: PCT/EP2005/050902
Publication No. WO2005/082375 A2)

In re Patent Application of:
Enrico Colli

International Application No.:
PCT/EP2005/050902

International Filing Date: March 1, 2005

Confirmation No.: N/A

Application No.: Not Yet Assigned

Filed: Concurrently Herewith

Art Unit: N/A

For: **TREATMENT OF INTERSTITIAL CYSTITIS
WITH VITAMIN D COMPOUNDS**

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicant invites the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicants respectfully request that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new U.S. national phase patent application submitted herewith.

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they have

U.S. National Phase Application of
PCT/EP2005/050902
Information Disclosure Statement

Attorney Docket No. 66073US(49949)

previously been transmitted by the International Bureau, along with the International Search Report, to all the Designated Offices in the corresponding international patent application No. PCT/EP2005/050902, filed March 1, 2005. A copy of the International Search Report is enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


Applicant submits that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 66073US(49949). A duplicate copy of this paper is enclosed.

Dated: August 25, 2006

Respectfully submitted,

By



Peter C. Lauro, Esq.

Registration No.: 32,360

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	66073US(49949)
-------	---	----	---	------------------------	----------------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)				
/KW/	BA**	-WO 2004/098612-A	11-18-2004	AB SCIENCE; MOUSSY, ALAIN; KINET, JEAN-PIERRE		
/KW/	BB**	-WO 2005/030223-A	04-07-2005	BIOXELL, INC; COLLI, ENRICO		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/KW/	CA**	MUTSCHLER E: "Arzneimittelwirkungen" 2001, WVG, STUTTGART, XP002340852, page 742 - page 743			
/KW/	CB**	BEERS ET AL: "Merck Manual" 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002340267, page 1893, column 2, paragraph 1 - paragraph 2			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

/Kevin Weddington/ (03/05/2009)

03/05/2009

Examiner Signature	Date Considered
--------------------	-----------------